What types of antibodies can be found on Luxbio.net
On luxbio.net, you can find a comprehensive and specialized catalog of research-grade antibodies, primarily focused on monoclonal and polyclonal antibodies designed for applications in immunology, cell biology, and cancer research. The core offerings include primary antibodies targeting a vast array of proteins, such as cytokines, kinases, transcription factors, and cell surface markers, alongside essential secondary antibodies conjugated to various enzymes and fluorophores for detection. The platform is particularly noted for its deep expertise in antibodies related to immune checkpoint proteins, apoptosis, and signal transduction pathways, providing critical tools for scientists in both academic and pharmaceutical settings.
The antibodies available are rigorously validated to ensure specificity, sensitivity, and lot-to-lot consistency, which is paramount for reproducible research. Validation data often includes Western Blot, Immunohistochemistry (IHC), Immunofluorescence (IF), and Flow Cytometry (FACS), providing researchers with the confidence needed for their experimental designs. For instance, an antibody against a key protein like PD-L1 would typically be supported by data showing clear bands at the correct molecular weight in Western Blots and specific membrane staining in IHC applications using relevant cell lines or tissue sections.
Beyond the standard offerings, Luxbio.net provides access to more specialized reagents like recombinant antibodies, which offer superior batch-to-batch consistency due to their production from engineered gene sequences. These are increasingly important for diagnostic development and therapeutic antibody discovery pipelines. The table below outlines the primary categories of antibodies available, highlighting their common targets and primary applications to give you a clear overview of the portfolio’s depth.
| Antibody Type | Key Characteristics | Example Targets | Primary Research Applications |
|---|---|---|---|
| Monoclonal Antibodies | High specificity; single epitope recognition; consistent production. | CD markers (CD3, CD19), Phospho-proteins (p-AKT, p-ERK), Viral Antigens. | Flow Cytometry, Therapeutic Development, Diagnostic Assays. |
| Polyclonal Antibodies | Recognize multiple epitopes; often higher sensitivity; robust for detecting denatured proteins. | Total protein forms (AKT, ERK), Housekeeping genes (GAPDH, Beta-Actin). | Western Blot, Immunohistochemistry, ELISA. |
| Secondary Antibodies | Conjugated to labels (HRP, Fluorescent dyes); anti-species specific (e.g., Anti-Rabbit, Anti-Mouse). | N/A – Designed to bind primary antibodies. | Signal amplification and detection across all immunoassays. |
| Recombinant Antibodies | Genetically engineered; superior reproducibility; defined sequence. | Immune Checkpoints (PD-1, CTLA-4), Cytokines (IL-2, TNF-alpha). | High-throughput Screening, CAR-T Cell Research, Biologics Discovery. |
| Phospho-Specific Antibodies | Detect post-translational modifications (phosphorylation); critical for signaling studies. | p-STAT3, p-JNK, p-p38 MAPK. | Cell Signaling Pathway Analysis, Drug Mechanism Studies. |
Diving deeper into the monoclonal antibodies, these are produced from a single clone of hybridoma cells, ensuring that every batch is identical. This is a critical advantage for long-term or multi-center studies where consistency is non-negotiable. For example, in cancer research, using a monoclonal antibody against HER2 ensures that the staining intensity and pattern in patient tissue samples can be reliably compared over time and across different laboratories. The development process for these antibodies at Luxbio often involves immunizing hosts with specific peptides or full-length recombinant proteins, followed by sophisticated screening processes to isolate clones with the desired specificity and affinity.
The polyclonal antibody offerings provide a different set of advantages. Because they are a mixture of antibodies recognizing different epitopes on the same antigen, they are often more sensitive in detecting low-abundance proteins, especially in techniques like Western Blot where the protein might be partially denatured. A researcher studying a novel protein with an unknown structure might initially choose a polyclonal antibody to increase the chances of detection. These are typically produced in hosts like rabbits or goats, and each batch is carefully characterized to ensure it meets performance benchmarks, though there can be more natural variation between batches compared to monoclonal ones.
When it comes to conjugated antibodies, the selection is extensive. Secondary antibodies are available conjugated to enzymes like Horseradish Peroxidase (HRP) for chemiluminescent detection or Alkaline Phosphatase (AP) for colorimetric assays. For fluorescence-based applications, you’ll find secondaries conjugated to a wide spectrum of fluorophores, including FITC, PE, Cy3, Cy5, and Alexa Fluor dyes (e.g., Alexa Fluor 488, 647), which are chosen for their brightness and photostability. The availability of cross-adsorbed secondary antibodies, which have been purified to minimize cross-reactivity with immunoglobulins from other species, is a key feature that allows for sophisticated multi-color experiments in flow cytometry or multiplex immunofluorescence.
The niche of phospho-specific antibodies is particularly strong. These reagents are essential for dissecting dynamic cellular signaling events. They are developed to recognize a protein only when it is phosphorylated at a specific amino acid residue (e.g., tyrosine, serine, threonine). The validation of these antibodies is exceptionally rigorous, often involving peptide inhibition assays where the signal is blocked by the phosphorylated peptide used as the immunogen but not by the non-phosphorylated counterpart. This confirms the antibody’s specificity and prevents false positives that could derail a research project. For a kinase like AKT, which is central to the PI3K/AKT/mTOR pathway, having reliable phospho-specific antibodies (e.g., for Ser473 or Thr308) is fundamental for testing the efficacy of new oncology drugs.
Another critical aspect of the offerings is the support provided for assay development. The product pages are not just simple listings; they are rich resources containing detailed protocols, recommended dilutions for different applications, and images of validation data. For a commonly used antibody like one against Beta-Actin (a loading control), the page might provide Western Blot data from five different cell lysates showing a single clean band at 42 kDa, IHC data from human liver tissue, and a suggested starting dilution of 1:1000 for Western Blot. This level of detail saves researchers valuable time and resources during experimental setup.
The scope of targets is continuously expanding based on the latest research trends. There is a significant focus on antibodies for immuno-oncology, including those targeting immune checkpoint proteins like PD-1, PD-L1, CTLA-4, LAG-3, and TIM-3. These are vital for characterizing the tumor microenvironment and developing next-generation immunotherapies. Similarly, there is a growing portfolio of antibodies for neuroscience, targeting proteins like Tau, Amyloid-beta, and various ion channels and receptors implicated in neurological diseases. The commitment is to provide not just products but solutions that are directly applicable to cutting-edge scientific challenges, making the platform a go-to resource for researchers who need reliable, high-performance immunological reagents to drive their discoveries forward.